188例儿童系统性红斑狼疮5年生存率及预后分析

doi:10.6040/j.issn.1671-7554.0.2022.0495

摘要/Abstract

摘要： 目的探讨儿童系统性红斑狼疮(SLE)的临床特点,分析其5年生存率、复发和死亡原因以及影响生存预后的因素,为改善cSLE的预后、指导治疗提供依据。方法回顾性收集2009年1月1日至2020年12月31日小儿肾脏风湿免疫科SLE患儿188例的临床资料,并行门诊或电话随访。使用非参数乘积法分析生存率,采用时序检验、比例风险模型行预后因素分析。结果 188例SLE患儿,男40例,女148例,平均发病年龄(10.64±2.12)岁,发病到确诊中位病程30(15,60)d。最常见的临床表现是发热、皮疹。患儿确诊时最常见合并肾脏损害及血液系统损害。随访期间,73例(38.8%)患儿病情复发,主要原因是依从性差、感染。16例患儿死亡,主要原因是依从性差、多脏器损害、感染、肾功能不全。患儿1、3、5年总体生存率分别为94.1%、92.9%、91.7%。单因素分析显示,心血管系统损害(χ2=4.464,P=0.035)、神经系统损害(χ2=6.545,P=0.011)、血液系统损害(χ2=3.888,P=0.049)、大量蛋白尿(χ2=5.641,P=0.018)、初诊疾病重度活动(χ2=4.679,P=0.031)、诱导治疗疾病无活动(χ2=7.561,P=0.006)、复发(χ2=13.786,P≤0.001)与SLE预后相关,进一步Cox多因素回归分析显示,心血管系统损害(HR=3.361,95%CI:1.251~9.029,P=0.016)、神经系统损害(HR=2.997,95%CI:1.076~8.349,P=0.036)、大量蛋白尿(HR=2.162,95%CI:1.079~4.334,P=0.030)、复发(HR=4.663,95%CI:1.666~13.049,P=0.003)是导致SLE预后不佳的独立危险因素。结论本研究SLE患儿主要临床表现以发热、皮疹最为多见,系统损害以肾脏损害、血液系统损害最为多见。合并心血管系统损害、神经系统损害、大量蛋白尿、疾病复发的SLE患儿5年总体预后不佳,治疗时积极控制脏器损害、及时降低蛋白尿、预防疾病复发是提高生存率的关键。

关键词: 系统性红斑狼疮, 儿童, 生存率, 预后

Abstract: Objective To summarize the clinical characteristics of childhood-onset systemic lupus erythematosus(cSLE), analyze the 5-year survival rate, causes of relapse and death, and factors affecting prognosis, in order to provide a basis for improving the prognosis and guiding the treatment. Methods Clinical data of 188 SLE patients treated during Jan. 1, 2009 and Dec. 31, 2020 were retrospectively collected and the patients were followed up in clinic or with telephone. The survival rate was analyzed using Kaplan-Meier method, and the prognostic factors were analyzed using Log-rank test and cox parametric regression analysis. Results Of the 188 children, 40 were male and 148 were female, mean age of onset were(10.64±2.12)years, median duration of illness from onset to diagnosis were 30(15, 60)days. The most common clinical manifestations were fever and rash. Renal damage and hematologic damage were often observed at diagnosis. During the follow-up, 73 children(38.8%)had relapse, mainly due to poor compliance and infection; 16 children died, mainly due to poor compliance, multiple organ damage, infection, and renal insufficiency. The 1-year, 3-year and 5-year survival rates were 94.1%, 92.9%, and 91.7%, respectively. Univariate analysis showed that cardiovascular system damage(χ2=4.464, P=0.035), neurological system damage(χ2=6.545, P=0.011), hematological system damage(χ2=3.888, P=0.049), massive proteinuria(χ2=5.641, P=0.018), severe activity of the initial disease(χ2=4.679, P=0.031), induction therapy disease inactivity(χ2=7.561, P=0.006), and relapse(χ2=13.786, P≤0.001)were associated with prognosis. Cox parametric regression analysis showed that cardiovascular system damage(HR=3.361, 95%CI: 1.251-9.029, P=0.016), neurological damage(HR=2.997, 95%CI: 1.076-8.349, P=0.036), massive proteinuria(HR=2.162, 95%CI: 1.079-4.334, P=0.030), and relapse(HR=4.663, 95%CI: 1.666-13.049, P=0.003)were independent risk factors of poor prognosis. Conclusion The main clinical manifestations of SLE are fever and rash, and systemic damages are renal damage and hematologic damage. The overall 5-year prognosis for patients complicated with cardiovascular damage, neurological damage, massive proteinuria and with recurrence is poor. Active control of organ damage, timely reduction of proteinuria, and prevention of recurrence are key to improving survival.

Key words: Systemic lupus erythematosus, Children, Survival rate, Prognosis

中图分类号:

R725.9

孔林笑语,孙书珍,余丽春,贾梦文. 188例儿童系统性红斑狼疮5年生存率及预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 69-76.

KONG Linxiaoyu, SUN Shuzhen, YU Lichun, JIA Mengwen. Analysis of 5-year survival rate and prognosis in 188 children with systemic lupus erythematosus[J]. Journal of Shandong University (Health Sciences), 2022, 60(12): 69-76.

参考文献

[1] Harry O, Yasin S, Brunner H. Childhood-onset systemic lupus erythematosus: a Review and update [J]. J Pediatr, 2018, 196: 22-30. doi: 10.1016/j.jpeds.2018.01.045.
[2] Trindade VC, Carneiro-Sampaio M, Bonfa E, et al. An update on the management of childhood-onset systemic lupus erythematosus [J]. Paediatr Drugs, 2021, 23(4): 331-347.
[3] Mina R, Brunner HI. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? [J]. Rheum Dis Clin North Am, 2010, 36(1): 53-80.
[4] Moghaddam B, Marozoff S, Li L, et al. All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study [J]. Rheumatology(Oxford), 2021, 61(1): 367-376.
[5] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J]. Arthritis Rheum, 1997, 40(9): 1725.
[6] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus [J]. Arthritis Rheum, 2012, 64(8): 2677-2686.
[7] 范晖, 闫银坤, 米杰. 中国3~17岁儿童性别、年龄别和身高别血压参照标准[J]. 中华高血压杂志, 2017, 25(5): 428-435. FAN Hui, YAN Yinkun, MI Jie. Updating blood pressure references for Chinese children aged 3-17 years [J]. Chinese Journal of Hypertension, 2017, 25(5): 428-435.
[8] Weening JJ, DAgati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited [J]. J Am Soc Nephrol, 2004, 15(2): 241-250.
[9] 全国儿童风湿病协作组. 儿童风湿病诊断及治疗专家共识(二)[J]. 临床儿科杂志, 2010, 28(11): 1089-1094. National Childrens Rheumatic Disease Collaboration Group. Diagnosis and treatment of pediatric rheumatic diseases: a consensus statement [J]. Journal of Clinical Pediatrics, 2010, 28(11): 1089-1094.
[10] 宋红梅. 儿童系统性红斑狼疮诊疗建议解读[J]. 中华儿科杂志, 2011, 49(7): 515-518. SONG Hongmei. The explanation of SGI-PS-CMA evidence-based recommendations for the diagnosis and management of juvenile systemic lupus erythematosus [J]. Chinese Journal of Pediatrics, 2011, 49(7): 515-518.
[11] 党西强, 易著文. 狼疮性肾炎诊治循证指南(2016)解读[J]. 中华儿科杂志, 2018, 56(2): 95-99. DANG Xiqiang, YI Zhuwen. Interpretation of evidence-based guideline on diagnosis and treatment of lupus nephritis(2016)[J]. Chinese Journal of Pediatrics, 2018, 56(2): 95-99.
[12] Wei Q, Wang W, Dong Y, et al. Five years follow-up of juvenile lupus nephritis: a single-center retrospective cohort study [J]. Ann Palliat Med, 2021, 10(7): 7351-7359.
[13] Ceccarelli F, Perricone C, Cipriano E, et al. Joint involvement in systemic lupus erythematosus: from pathogenesis to clinical assessment [J]. Semin Arthritis Rheum, 2017, 47(1): 53-64.
[14] Groot N, Shaikhani D, Teng YKO, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus [J]. Arthritis Rheumatol, 2019, 71(2): 290-301.
[15] Rodsaward P, Prueksrisakul T, Deekajorndech T, et al. Oral ulcers in juvenile-onset systemic lupus erythematosus: a review of the literature [J]. Am J Clin Dermatol, 2017, 18(6): 755-762.
[16] Joo YB, Park SY, Won S, et al. Differences in clinical features and mortality between childhood-onset and adult-onset systemic lupus erythematosus: a prospective single-center study [J]. J Rheumatol, 2016, 43(8): 1490-1497.
[17] 李正芳, 吴雪, 罗采南, 等. 系统性红斑狼疮五年生存率及影响预后的因素[J]. 新疆医学, 2021, 51(11): 1229-1231. LI Zhengfang, WU Xue, LUO Cainan, et al. Analysis of 5-year survival rate and prognostic indicators of systemic lupus erythematosus [J]. Journal of Management, 2021, 51(11): 1229-1231.
[18] Tucker LB, Uribe AG, Fernández M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort(LUMINA LVII)[J]. Lupus, 2008, 17(4): 314-322.
[19] Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort [J]. Arthritis Rheum, 2012, 64(7): 2356-2365.
[20] Ravelli A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus [J]. Curr Opin Rheumatol, 2005, 17(5): 568-573.
[21] Lee PY, Yeh KW, Yao TC, et al. The outcome of patients with renal involvement in pediatric-onset systemic lupus erythematosus: a 20-year experience in Asia [J]. Lupus, 2013, 22(14): 1534-1540.
[22] Wong SN, Tse KC, Lee TL, et al. Lupus nephritis in Chinese children - a territory-wide cohort study in Hong Kong [J]. Pediatr Ne-phrol, 2006, 21(8): 1104-1112.
[23] Fatemi A, Matinfar M, Smiley A. Childhood versus adult-onset systemic lupus erythematosus: long-term outcome and predictors of mortality [J]. Clin Rheumatol, 2017, 36(2): 343-350.
[24] Tektonidou MG, Lewandowski LB, Hu J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016 [J]. Ann Rheum Dis, 2017, 76(12): 2009-2016.
[25] 程程, 文思佳, 林知朗, 等. 儿童狼疮性肾炎的疗效及预后分析[J]. 中华儿科杂志, 2021, 59(9): 730-736. CHENG Cheng, WEN Sijia, LIN Zhilang, et al. Treatment effectiveness and long-term prognosis of childhood-onset lupus nephritis[J]. Chinese Journal of Pediatrics, 2021, 59(9): 730-736.
[26] Davidson JE, Fu Q, Ji B, et al. Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis[J]. J Rheumatol, 2018, 45(5): 671-677.
[27] Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus [J]. J Autoimmun, 2016, 74: 41-72. doi: 10.1016/j.jaut.2016.06.013.
[28] Monahan RC, Fronczek R, Eikenboom J, et al. Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: a retrospective analysis from a tertiary referral center in the Netherlands [J]. Lupus, 2020, 29(14): 1892-1901.
[29] Williams FM, Chinn S, Hughes GR, et al. Critical illness in systemic lupus erythemato-sus and the antiphospholipid syndrome [J]. Ann Rheum Dis, 2002, 61(5): 414-421.
[30] Chen J, Tang Y, Zhu M, et al. Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis [J]. Clin Rheumatol, 2016, 35(10): 2437-2448.
[31] 何晓蕾, 徐清, 王伦文. 系统性红斑狼疮并发心血管疾病的临床研究[J]. 临床心血管病杂志, 2013, 29(8): 633-634. HE Xiaolei, XU Qing, WANG Lunwen. Clinical study of systemic lupus erythematosus patients with cardiovascular disease [J]. Journal of Clinical Cardiology, 2013, 29(8): 633-634.
[32] 张培敏, 樊蓉, 李想, 等. 泼尼松联合霉酚酸酯对比环磷酰胺治疗狼疮性肾炎的系统评价[J]. 实用药物与临床, 2015, 18(2): 130-135. ZHANG Peimin, FAN Rong, LI Xing, et al. Mycophenolate mofetil versus cyclophospha-mide combined with prednisone in induction therapy for lupus nephritis: a systematic review [J]. Practical Pharmacy and Clinical Remedies, 2015, 18(2): 130-135.
[33] Jin SY, Huang DL, Dang XQ, et al. Lupus glomerulonephritis in 788 Chinese children: a multi-centre clinical and histopathological analysis based on 549 renal biopsies [J]. Paediatr Int Child Heal, 2017, 37(4): 286-291.
[34] 黄建萍, 都娟. 儿童系统性红斑狼疮复发与持续不缓解[J]. 中国实用儿科杂志,2012, 27(9): 657-659.
[35] Lopes SRM, Gormezano NWS, Gomes RC, et al. Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups [J]. Lupus, 2017, 26(9): 996-1001.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed